Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10Gynecologic 5Genitourinary 4Endocrine 4NET 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 23Cyclophosphamide 23fludarabine phosphate 18Tacrolimus 16ruxolitinib 15Melphalan 15Azacitidine 14venetoclax 13Whole-Body Irradiation 12Mycophenolic Acid 12Cytarabine 11Busulfan 11Thiotepa 9Specimen Handling 9Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Decitabine 8Biopsy 8Peripheral Blood Stem Cell Transplantation 7Imatinib Mesylate 7decitabine and cedazuridine drug combination 6Sirolimus 6Methotrexate 6thymoglobulin 5nilotinib 5X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Everolimus × Myeloid × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡